0.00
+0(+0.00%)
Currency In USD
Address
9301 Amberglen Boulevard
Austin, TX 78729
United States of America
Phone
512 869 1555
Website
Sector
Healthcare
Industry
Biotechnology
Employees
62
First IPO Date
February 04, 2005
| Name | Title | Pay | Year Born |
| Dr. Eric E. Poma Ph.D. | Interim Chief Financial Officer, Treasurer, Principal Acc. Officer, Chief Executive Officer, Chief Scientific Officer & Director | 723,809 | 1972 |
| Dr. Grace Kim Ph.D. | Chief Strategy Officer & Head of IR | 0 | N/A |
| Ms. Kristen Quigley B.A. | Chief Operating Officer | 0 | 1971 |
| Dr. Michelle Iwamoto-Fan J.D., Ph.D. | Senior Vice President & General Counsel | 0 | N/A |
| Dr. Joseph Phillips Ph.D. | Senior Vice President & Head of CMC Development | 0 | N/A |
| Dr. Chris Moore Ph.D. | Senior Vice President and Head of Preclinical Development & Translational Medicine | 0 | N/A |
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.